Pfizer Inc (PFE)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 25.39% | 36.16% | 47.79% | 50.52% | 47.75% | 48.23% | 46.07% | 43.38% | 42.53% | 44.97% | 43.41% | 43.62% | 43.63% | 41.74% | 43.14% | 44.06% | 43.79% | 43.72% | 44.35% | 43.63% |
| Operating profit margin | -30.43% | -9.88% | 6.26% | 16.23% | 16.32% | 15.85% | 14.12% | 9.02% | 4.16% | 6.74% | -2.43% | -10.03% | -12.96% | -15.93% | -12.98% | -9.79% | -10.15% | -8.61% | -6.79% | -7.41% |
| Pretax margin | 1.72% | 15.16% | 29.13% | 34.34% | 34.59% | 32.86% | 31.37% | 29.31% | 29.32% | 33.07% | 27.81% | 26.02% | 22.88% | 13.12% | 33.12% | 32.58% | 33.15% | 33.47% | 20.51% | 21.14% |
| Net profit margin | 3.62% | 15.29% | 27.55% | 31.25% | 31.27% | 29.54% | 28.76% | 26.92% | 27.04% | 30.65% | 24.85% | 24.16% | 21.99% | 16.41% | 29.25% | 31.54% | 31.99% | 31.47% | 24.25% | 21.88% |
Pfizer Inc.'s profitability ratios have shown fluctuations over the past eight quarters. The company's gross profit margin has generally been favorable, ranging from 57.34% to 69.42% during the period. This indicates Pfizer's ability to effectively manage production costs and generate profit from its core operations.
However, the operating profit margin has displayed more variability, with figures ranging from 5.74% to 36.25%. This implies that Pfizer's operating expenses and other costs have had a notable impact on its profitability in certain quarters.
The pretax margin has also shown fluctuation, with values ranging from 1.81% to 34.37%. This ratio reflects Pfizer's ability to efficiently manage its tax obligations and expenses before accounting for taxes.
In terms of net profit margin, Pfizer has demonstrated consistent profitability, with margins ranging from 3.62% to 31.26% over the period. This ratio indicates the company's overall profitability after all expenses, including taxes, have been taken into account.
Overall, while Pfizer has maintained strong gross and net profit margins, there have been fluctuations in operating profit and pretax margins, suggesting some variability in financial performance over the past eight quarters.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -7.84% | -3.15% | 2.22% | 7.71% | 8.31% | 8.18% | 7.37% | 4.55% | 1.87% | 2.39% | -0.73% | -2.79% | -3.50% | -4.19% | -3.48% | -2.90% | -3.04% | -2.61% | -2.27% | -2.50% |
| Return on assets (ROA) | 0.93% | 4.87% | 9.76% | 14.85% | 15.92% | 15.24% | 15.01% | 13.58% | 12.14% | 10.84% | 7.51% | 6.73% | 5.94% | 4.32% | 7.83% | 9.34% | 9.56% | 9.54% | 8.11% | 7.38% |
| Return on total capital | 2.13% | 7.74% | 15.06% | 24.99% | 27.96% | 27.43% | 27.35% | 24.10% | 22.16% | 19.92% | 14.82% | 12.40% | 10.94% | 6.69% | 15.12% | 17.38% | 18.35% | 18.56% | 12.67% | 13.17% |
| Return on equity (ROE) | 2.38% | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 25.67% | 18.21% | 15.57% | 14.48% | 11.85% | 21.67% | 23.83% | 25.38% | 24.91% | 21.24% | 19.52% |
Pfizer Inc.'s profitability ratios show a fluctuating trend over the past eight quarters. The Operating return on assets (Operating ROA) decreased from 18.90% in Q4 2022 to 1.48% in Q4 2023. This indicates a decline in the company's operating efficiency in generating profits from its assets. Similarly, Return on assets (ROA) also saw a decrease from 15.91% in Q4 2022 to 0.94% in Q4 2023, reflecting a decrease in overall profitability.
However, Return on total capital and Return on equity (ROE) display a downward trend from Q4 2022 to Q4 2023. Return on total capital decreased from 29.46% to 3.15%, and ROE declined from 32.80% to 2.38% over the same period. These reductions indicate a decrease in the company's ability to generate returns for both debt and equity investors.
It is important for investors and analysts to closely monitor Pfizer Inc.'s profitability ratios to understand the company's ability to generate profits from its assets and capital, as well as its efficiency in utilizing equity.